Modalis Therapeutics (TSE:4883) FCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4883 Modalis Therapeutics Corp TSE:4883
20 GF Score
Price 円34.00
! 2 Warning Signs
View Full Analysis

What is Modalis Therapeutics FCF Margin %?

Modalis Therapeutics TSE:4883 +3.03% 20 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 963 Drug Manufacturers companies, Modalis Therapeutics ranks worse than 103842.06% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Modalis Therapeutics's Free Cash Flow for the three months ended in Dec. 2025 was 円0.00 Mil. Modalis Therapeutics's Revenue for the three months ended in Dec. 2025 was 円0.00 Mil. Therefore, Modalis Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Modalis Therapeutics's current FCF Yield % is -64.76%.

The historical rank and industry rank for Modalis Therapeutics's FCF Margin % or its related term are showing as below:


During the past 8 years, the highest FCF Margin % of Modalis Therapeutics was 26.36%. The lowest was -77688.82%. And the median was -352.80%.

TSE:4883's FCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.57
* Ranked among companies with meaningful FCF Margin % only.

Modalis Therapeutics FCF Margin % Related Terms

Modalis Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Modalis Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Modalis Therapeutics FCF Margin % Chart

Modalis Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial -77,688.82 -5,168.05 0.00 0.00 0.00

Modalis Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4883 vs ZTS, UTHR: FCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Modalis Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Modalis Therapeutics FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Modalis Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Modalis Therapeutics's FCF Margin % falls into.


TSE:4883
20GF Score
Modalis Therapeutics Corp TSE:4883
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Modalis Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Modalis Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-2120.98/0
= %

Modalis Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Modalis Therapeutics (TSE:4883) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Modalis Therapeutics and its competitors. According to the industry distribution chart, Modalis Therapeutics ranks #999999 out of 963 companies in the Drug Manufacturers industry.
Is Modalis Therapeutics' FCF Margin % too high?
Modalis Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Modalis Therapeutics ranks #999999 out of 963 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #999999 out of 963 companies for FCF Margin %. This places Modalis Therapeutics in the lower half of its industry. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Modalis Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modalis Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Modalis Therapeutics Business Description

Address 3-11-5 Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score

Get the complete analysis for TSE:4883

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円34.00
Price